20020177477

21 MAR 2002

162162

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 May 2001 (10.05.2001)

PCT

(10) International Publication Number
WO 01/32651 A1

(51) International Patent Classification[7]: C07D 401/12, A61P 9/00, 35/00

(21) International Application Number: PCT/GB00/04181

(22) International Filing Date:
1 November 2000 (01.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
99402759.7 5 November 1999 (05.11.1999) EP
99402877.7 19 November 1999 (19.11.1999) EP

(71) Applicant *(for all designated States except MG, US)*: **ASTRAZENECA AB** [SE/SE]; S-151 85 Sodertalje (SE).

(71) Applicant *(for MG only)*: **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HENNEQUIN, Laurent, François, André** [FR/FR]; Z.I. La Pompelle, Boîte postale 1050, F-51689 Reims Cedex 2 (FR). **STOKES, Elaine, Sophie, Elizabeth** [GB/GB]; Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **THOMAS, Andrew, Peter** [GB/GB]; Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(74) Agent: **PHILLIPS, Neil, Godfrey, Alasdair**; AstraZeneca, Global Intellectual Property, P.O. Box 272, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4GR (GB).


(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *With international search report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS



(I)

(57) Abstract: The invention relates to quinazoline derivatives of formula (I), wherein m is an integer from 1 to 3; R^1 represents halogeno or C_{1-3}alkyl; X^1 represents -O-; R^2 is selected from one of the following three groups: 1) C_{1-5}alkylR^3 (wherein R^3 is piperidin-4-yl which may bear one or two substituents selected from hydroxy, halogeno, C_{1-4}alkyl, C_{1-4}hydroxyalkyl and C_{1-4}alkoxy; 2) C_{2-5}alkenylR^3 (wherein R^3 is as defined hereinbefore); 3) C_{2-5}alkynylR^3 (wherein R^3 is as defined hereinbefore); and wherein any alkyl, alkenyl or alkynyl group may bear one or more substituents selected from hydroxy, halogeno and amino; and salts thereof; processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

WO 01/32651 A1

ACTION